22.418 articles found

Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.

Alonso-Frech F, Zamarbide I, Alegre M, Rodríguez-Oroz MC, Guridi J, Manrique M, Valencia M, Artieda J, Obeso JA.

Brain · 2006-05-09

DOI: 10.1093/brain/awl103PMID: 16684788

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

WEINER DAVID M, DAVIS ROBERT E, BRANN MARK R.

· 2006-05-03

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

WEINER DAVID M, DAVIS ROBERT E, BRANN MARK R.

· 2006-05-03

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

WEINER DAVID M, DAVIS ROBERT E, BRANN MARK R.

· 2006-05-03

Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis.

Porcel J, Montalban X.

J Neurol Sci · 2006-05-03

DOI: 10.1016/j.jns.2005.07.021PMID: 16674980

A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase.

Wu SP, Fu AL, Wang YX, Yu LP, Jia PY, Li Q, Jin GZ, Sun MJ.

Biochem Biophys Res Commun · 2006-05-02

DOI: 10.1016/j.bbrc.2006.03.247PMID: 16762325

USE OF CYTOKINE-DERIVED PEPTIDES IN TREATMENT OF PAIN AND NEURODEGENERATIVE DISEASE

CHAVEZ RAYMOND A, JOHNSON KIRK W, SHUMILLA JENNIFER, SANFTNER LAURA.

· 2006-05-01

Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease

CHAVEZ RAYMOND A, JOHNSON KIRK W, SHUMILLA JENNIFER, SANFTNER LAURA.

· 2006-05-01

Treatment of Japanese restless legs syndrome patients with cabergoline: an open clinical preliminary trial.

Aizawa H, Aburakawa Y, Suzuki Y, Enomoto H, Makita Y, Kikuchi K, Kimura T, Yahara O.

Intern Med · 2006-05-01

DOI: 10.2169/internalmedicine.45.1555PMID: 16679700

Plasticity of the motor cortex in Parkinson's disease patients on and off therapy.

Bagnato S, Agostino R, Modugno N, Quartarone A, Berardelli A.

Mov Disord · 2006-05-01

DOI: 10.1002/mds.20778PMID: 16353175

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.

Strong JA, Dalvi A, Revilla FJ, Sahay A, Samaha FJ, Welge JA, Gong J, Gartner M, Yue X, Yu L.

Mov Disord · 2006-05-01

DOI: 10.1002/mds.20785PMID: 16435402

Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.

Marin C, Aguilar E, Obeso JA.

Mov Disord · 2006-05-01

DOI: 10.1002/mds.20780PMID: 16437585